chemfish

News

Contact

Hunan chemfish Pharmaceutical co.,Ltd .

Tel      :0731-85567275

Phone: 18932438858

QQ      : 3406412061

QQ      : 156782042

Email : sales@chemfish.com
Website: www.chemfish.com

Add    : No.10048, xiangjiang centry bulding ,kaifu district ,changsha city ,Hunan
 

Position: Home > News > Industry News
Industry News

Knee Osteoarthritis Pain Treatment: Chondroitin Sulfate + Glucosamine Hydrochloride vs Celecoxib

Knee osteoarthritis is a degenerative pathological changes based on the disease, mostly in the elderly population. A study conducted in the United States, Canada, Spain, and other scientists published in "MonRheum Dis." In January 2016 compared the efficacy of chondroitin sulfate + glucosamine hydrochloride and celecoxib in the treatment of knee osteoarthritis and severe pain Sex and security.

 

OBJECTIVE: To compare the efficacy and safety of chondroitin sulfate + glucosamine hydrochloride (CS + GH) vs celecoxib in patients with knee osteoarthritis and severe pain.

 

METHODS: A double-blind, multicenter, osteoarthritis SYSADOA intervention trial (MOVES) was conducted in France, Germany, Poland and Spain, and 606 Kellgrenand Lawrence grades 2 to 3 were evaluated for knee osteoarthritis and moderate to severe pain [Xi'an And the McMaster bone arthritis index (WOMAC) score ≥301; measure 0 ~ 500] patients with CS + GHvs celecoxib treatment. Patients were randomized to receive 400 mg CS + 500 mg GH 3 times a day or celecoxib 200 mg / day for 6 months. The primary outcome was an average reduction in WOMAC pain from baseline to 6 months. Secondary outcomes include WOMAC function and stiffness, visual analogue of pain scores, presence of joint swelling / effusion, rescue drug consumption, clinical trials of rheumatology, and osteoarthritis study. The OMERACT-OARSI standard and EuroQoL- 5D.

 

Results: The mean change in WOMAC pain in the CS + GH group was -18.5.7 (-200.3-171.1) (50.1% reduction), and the celecoxib group was -186.8 (-201.7-171.9) 50.2%), in line with the -40: -1.11 non-inferiority limit (-22.0 ~ 19.8; p = 0.92). All sensitivity analysis is consistent with the results. At 6 months, 79.7% of the patients in the combined group and 79.2% of the patients in the celecoxib group met the OMERACT-OARSI standard. The decrease in joint swelling in both groups was reduced by> 50%; a similar reduction was observed for effusion. No differences were observed in other secondary outcomes. Adverse events were similar and distributed between the two groups.

 

CONCLUSIONS: CS + GH was associated with celecoxib in reducing pain, stiffness, functional limitations, and joint swelling / effusion in patients with painful knee osteoarthritis for 6 months, and the safety was good.

 

Chemfish dedicated to provide high quality chondroitin sulfate + glucosamine hydrochloride  with GMP certifications for drug company .Please feel free contact us at :sales@chemfish.com

 

Hits:  UpdateTime:2017-02-27 11:44:19  【Printing】  【Close
Online 
sales sales sales
sale01 sale01
Email to us
Feedback